Analyst Ratings For Alder Biopharmaceuticals Inc (NASDAQ:ALDR)
Today, Alder Biopharmaceuticals Inc (NASDAQ:ALDR) stock was downgraded by Mizuho from Buy to Neutral.
There are 8 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on Alder Biopharmaceuticals Inc (NASDAQ:ALDR) is Buy with a consensus target price of $23.5455 per share, a potential 75.71% upside.
Some recent analyst ratings include
- 10/12/2018-Alder Biopharmaceuticals Inc (NASDAQ:ALDR) gets downgraded to Neutral by Mizuho
- 9/10/2018-Alder Biopharmaceuticals Inc (NASDAQ:ALDR) has coverage initiated with a Underweight ➝ Underweight rating and $19.00 price target
- 8/22/2018-Alder Biopharmaceuticals Inc (NASDAQ:ALDR) has coverage initiated with a Neutral rating and $21.00 price target
- 8/7/2018-Alder Biopharmaceuticals Inc (NASDAQ:ALDR) has coverage initiated with a Buy rating and $30.00 price target
- On 10/1/2018 Jeffrey T L Smith, Director, sold 5,040 with an average share price of $15.54 per share and the total transaction amounting to $78,321.60.
- On 10/1/2018 John A Latham, Insider, sold 24,999 with an average share price of $15.44 per share and the total transaction amounting to $385,984.56.
- On 9/4/2018 Jeffrey T L Smith, Director, sold 5,040 with an average share price of $18.00 per share and the total transaction amounting to $90,720.00.
- On 9/4/2018 John A Latham, Insider, sold 24,999 with an average share price of $17.99 per share and the total transaction amounting to $449,732.01.
- On 8/1/2018 Jeffrey T L Smith, Director, sold 5,040 with an average share price of $19.54 per share and the total transaction amounting to $98,481.60.
- On 8/1/2018 John A Latham, Insider, sold 24,999 with an average share price of $19.55 per share and the total transaction amounting to $488,730.45.
- On 7/2/2018 Jeffrey T L Smith, Director, sold 12,161 with an average share price of $15.49 per share and the total transaction amounting to $188,373.89.
About Alder Biopharmaceuticals Inc (NASDAQ:ALDR)
Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions in the United States, Australia, and Ireland. The company's lead pivotal-stage product candidate, Eptinezumab, a monoclonal antibody inhibiting calcitonin gene-related peptide, which is in Phase III pivotal trials for the prevention of migraine. Its product candidate pipeline also includes ALD1910, a preclinical monoclonal antibody that targets pituitary adenylate cyclase-activating polypeptide-38; and Clazakizumab, that has completed two Phase 2b clinical trials designed to block the pro-inflammatory cytokine IL-6. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.
Recent Trading Activity for Alder Biopharmaceuticals Inc (NASDAQ:ALDR)
Shares of Alder Biopharmaceuticals Inc closed the previous trading session at 13.40 −0.32 2.33% with 621300 shares trading hands.